| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Oncology, Oulu University Hospital, Finland
1 Department of Medical Informatics, Oulu University Hospital, Finland
2 Department of Internal Medicine, Oulu University Hospital, Finland
(Requests for offprints should be addressed to G Blanco, Department of Clinical Oncology, Oulu University Hospital, PL 22, FIN-90229 Oulu, Finland; Email: guillermo.blanco{at}ppsph.fi)
Differentiated thyroid carcinomas (DTC) (papillary, follicular and follicular type of papillary) have a favourable prognosis, but a proportion of patients develop recurrences and eventually die of the disease. Various prognostic factors have been identified and been used to create the current staging classifications (AGES, AMES, MACIS, EORTC, UICC-TNM). We examined 499 DTC patients retrospectively to validate known prognostic factors that enable them to be recognised as having either a low or a high risk of death related to a recurrence of DTC, by reference to the current staging classifications. Sixty-nine of them (14%) had local or distant recurrences, the mean time to recurrence being 7.7 years. The 10-year disease-free survival rate was 80%, and the ten-year overall survival rate for the entire group was 91%, with a mean survival time of 8.7 years. Male gender, a follicular type of tumour, larger tumour size, extrathyroidal invasion outside the capsule and nodal metastases were all related to a higher incidence of tumour recurrence, and the follicular type of histology, age >45 years, larger tumour size and local invasion entailed poorer survival. The AMES and to some extent the EORTC classification were not reproducible in this material, mainly because some prognostic variants were no longer encountered or were insufficient in number to allow reliable conclusions to be drawn. The MACIS staging classification leaves the definition of the intermediate and high risk groups too wide and is therefore not very reliable. Pooling of stages I and II improved the relevance of the TNM classification. All the current staging classifications are able to discern a low risk DTC group well. We achieved a highly accurate definition of risk in the present material using only two parameters, age (cut-off value 50 years) and extracapsular invasion of the thyroid gland.
This article has been cited by other articles:
|
|
 |
|
  N. A. Johnson and M. E. Tublin Postoperative Surveillance of Differentiated Thyroid Carcinoma: Rationale, Techniques, and Controversies Radiology, November 1, 2008; 249(2): 429 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Toniato, I. Boschin, D. Casara, R. Mazzarotto, D. Rubello, and M. Pelizzo Papillary Thyroid Carcinoma: Factors Influencing Recurrence and Survival Ann. Surg. Oncol., May 1, 2008; 15(5): 1518 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hu, J. Clark, R. J. Payne, S. Eski, P. G. Walfish, and J. L. Freeman Extrathyroidal Extension in Well-Differentiated Thyroid Cancer: Macroscopic vs Microscopic as a Predictor of Outcome Arch Otolaryngol Head Neck Surg, July 1, 2007; 133(7): 644 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Y. Lam, C. Y. Lo, P. Leung, B. H. H. Lang, W. F. Chan, and J. M. Luk Clinicopathological Roles of Alterations of Tumor Suppressor Gene p16 in Papillary Thyroid Carcinoma Ann. Surg. Oncol., May 1, 2007; 14(5): 1772 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, and K.-Y. Wan Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre Endocr. Relat. Cancer, March 1, 2007; 14(1): 29 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H.-H. Lang, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, and K.-Y. Wan Prognostic Factors in Papillary and Follicular Thyroid Carcinoma: Their Implications for Cancer Staging Ann. Surg. Oncol., February 1, 2007; 14(2): 730 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B T Verkooijen, D. Rietbergen, J. W Smit, J. A Romijn, and M. P M Stokkel A new functional parameter measured at the time of ablation that can be used to predict differentiated thyroid cancer recurrence during follow-up Eur. J. Endocrinol., January 1, 2007; 156(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-M. Yu, C.-Y. Lo, W.-F. Chan, K.-Y. Lam, P. Leung, and J. M. Luk Increased Expression of Vascular Endothelial Growth Factor C in Papillary Thyroid Carcinoma Correlates with Cervical Lymph Node Metastases Clin. Cancer Res., November 15, 2005; 11(22): 8063 - 8069. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
